CSIMarket
 


Crispr Therapeutics Ag  (CRSP)
Other Ticker:  
 

Crispr Therapeutics Ag's Total Debt to Equity

CRSP's quarterly Total Debt to Equity and Total Debt, Equity growth


In the third quarter 2023 Crispr Therapeutics Ag did not have Total Debt.

Within Biotechnology & Pharmaceuticals industry Crispr Therapeutics Ag achieved the lowest Total Debt to Equity in the third quarter 2023. While total ranking remained the same in the third quarter 2023 compared to the previous quarter at no. .

Explain Debt to Equity Ratio?
What is the structure of CRSP´s Total Debt?
How valuable is the CRSP´s Equity?


CRSP Total Debt to Equity (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change -11.57 % -13.14 % -17.37 % -21.84 % -22.24 %
Y / Y Total Debt Change - - - - -
Total Debt to Equity MRQ - - - - -
CRSP's Total Ranking # # # # #
Seq. Equity Change -4.86 % -2.1 % -1.1 % -4.02 % -6.55 %
Seq. Total Debt Change - - - - -



Total Debt to Equity third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall Market #


Total Debt to Equity Statistics
High Average Low
0 0 0
 




Financial Statements
Crispr Therapeutics Ag's Equity $ 1,728 Millions Visit CRSP's Balance sheet
Crispr Therapeutics Ag's Total Debt $ 0 Millions Visit CRSP's Balance sheet
Source of CRSP's Sales Visit CRSP's Sales by Geography


Cumulative Crispr Therapeutics Ag's Total Debt to Equity

CRSP's Total Debt to Equity for the trailling 12 Months

CRSP Total Debt to Equity

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth -11.57 % -13.14 % -17.37 % -21.84 % -22.24 %
Y / Y Total Debt TTM Growth - - - - -
Total Debt to Equity TTM - - - - -
Total Ranking TTM
Seq. Equity TTM Growth -4.86 % -2.1 % -1.1 % -4.02 % -6.55 %
Seq. Total Debt TTM Growth - - - - -


On the trailing twelve months basis During the twelve months ending III Quarter 2023 Crispr Therapeutics Ag did not have Total Debt .
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry CRSP recorded the lowest Total Debt to Equity. While total ranking remained unchanged compared to previous 12 month period at no. 0.

Explain Debt to Equity Ratio?
What is the structure of CRSP´s Total Debt?
How valuable is the CRSP´s Equity?

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Within the Market #


trailing twelve months Total Debt to Equity Statistics
High Average Low
0 0 0
 




Companies with similar Total Debt to Equity in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Total Debt to EquitySep 30 2023 MRQ Total DebtSep 30 2023 MRQ Equity

Date modified: 2023-11-07T12:58:35+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com